Key Takeaways
- • Rhenman & Partners Asset Management, a Swedish healthcare investment boutique, is expanding its fund range with a new long-biased long/short equity fund offering.
- • The flagship fund, Rhenman Healthcare Next Generation L/S, focuses on innovative micro-, small- and mid-cap healthcare companies under the leadership of Chief Investment Officer Kaspar Hållsten.
- • The firm is pursuing European expansion to broaden its institutional client base, according to CEO Teresa Isele.
- • The launch reflects growing institutional appetite for specialized healthcare sector strategies amid a healthcare venture investment market tracking toward approximately $49 billion annually in 2026.
Summary
Rhenman & Partners Asset Management, a Swedish healthcare-focused investment boutique, is broadening its product suite by introducing a long-biased long/short equity fund to complement its existing offerings. The expansion positions the firm to capture institutional capital in the specialized healthcare investment space, a sector experiencing structural consolidation after elevated venture investment levels in prior years.
The new fund, Rhenman Healthcare Next Generation L/S, is led by Chief Investment Officer Kaspar Hållsten and targets innovative healthcare companies at the micro-, small- and mid-cap scale. This positioning reflects a strategic focus on emerging healthcare businesses rather than large-cap pharmaceutical or established medical device manufacturers, offering institutional investors exposure to earlier-stage innovation within a long/short framework that permits downside hedging.
CEO Teresa Isele has signaled that Rhenman & Partners intends to expand its European customer base, suggesting the fund launch is part of a broader geographic growth strategy. The timing of this expansion aligns with broader market trends: healthcare venture investment is expected to reach approximately $49 billion in 2026, marking a recalibration from the 2021 peak toward what analysts characterize as a "more stable market." This environment creates opportunities for specialized asset managers to consolidate institutional relationships in a sector experiencing normalization after years of elevated capital flows.
The fund launch underscores institutional investor demand for thematic healthcare strategies that combine concentrated exposure to innovation with portfolio risk management tools. For hedge fund managers and institutional allocators seeking healthcare sector exposure, the introduction of specialized Nordic-based long/short strategies diversifies the competitive landscape beyond traditional U.S. and broader European healthcare investment platforms.
The new fund, Rhenman Healthcare Next Generation L/S, is led by Chief Investment Officer Kaspar Hållsten and targets innovative healthcare companies at the micro-, small- and mid-cap scale. This positioning reflects a strategic focus on emerging healthcare businesses rather than large-cap pharmaceutical or established medical device manufacturers, offering institutional investors exposure to earlier-stage innovation within a long/short framework that permits downside hedging.
CEO Teresa Isele has signaled that Rhenman & Partners intends to expand its European customer base, suggesting the fund launch is part of a broader geographic growth strategy. The timing of this expansion aligns with broader market trends: healthcare venture investment is expected to reach approximately $49 billion in 2026, marking a recalibration from the 2021 peak toward what analysts characterize as a "more stable market." This environment creates opportunities for specialized asset managers to consolidate institutional relationships in a sector experiencing normalization after years of elevated capital flows.
The fund launch underscores institutional investor demand for thematic healthcare strategies that combine concentrated exposure to innovation with portfolio risk management tools. For hedge fund managers and institutional allocators seeking healthcare sector exposure, the introduction of specialized Nordic-based long/short strategies diversifies the competitive landscape beyond traditional U.S. and broader European healthcare investment platforms.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.